Trial Profile
Fluorine-18 AV 1451 positron emission tomography in patients with non-Alzheimer's disease neurodegenerative syndromes associated with tau-positive or tau-negative pathology
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Oct 2015
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Chronic brain damage; Corticobasal degeneration; Dementia; Progressive supranuclear palsy
- Focus Diagnostic use
- 21 Oct 2015 New trial record